Paul Johnson

Paul Johnson did not discover entrepreneurship at a Stanford seminar or a Y Combinator interview. He discovered it in his family's garage in rural Worcestershire, stringing tennis rackets and shipping sports equipment he'd taught himself to sell online at 17, writing PHP code during his lunch break at school because there were orders to process and no one else to do it.

That origin story - hands-on, self-taught, relentlessly practical - explains almost everything about what came next. Johnson studied computer science and business at the University of Worcester, then moved through a series of digital commerce roles that took him to the edges of industries most people hadn't thought to digitize yet: pet supplies, pharmacy chains, sports goods. He ran the UK's largest online pet retailer at zooplus and became Head of Online for Lloyd's Pharmacy, one of Britain's biggest drugstore chains. He had a talent for seeing where a legacy industry was vulnerable to a faster, cheaper, more convenient version of itself.

By 2013, the industry he wanted to take on was healthcare. He moved from the English countryside to San Francisco - a relocation that signals either ambition or delusion, depending on when you're watching - and co-founded Lemonaid Health. The premise was simple and radical: what if you could see a doctor and get a prescription on your phone, in minutes, for a fraction of the cost?

Lemonaid Health became the first U.S. nationwide telehealth app. Not first in a particular state, or first for a particular condition, but first across the country. It launched the first national digital mental health service for anxiety and depression patients. It built the first fully digital hypertension treatment platform. In eight years, the company raised over $60 million, scaled to nearly 200 employees, and helped millions of Americans access care they couldn't have accessed otherwise.

In November 2021, 23andMe acquired Lemonaid Health for $400 million. The price represented more than a 10x return on the Series A. The deal happened in part because Johnson sat down with 23andMe founder Anne Wojcicki at her home and immediately saw what combining genetic data with digital healthcare delivery could mean: personalized medicine at scale, built on the infrastructure Lemonaid had spent eight years constructing.

After the acquisition, Johnson became Chief Operating Officer of the 23andMe consumer business, continuing to run Lemonaid's operations under the new parent. But the founder's itch doesn't disappear when you join someone else's org chart. By 2022, he was coaching other CEOs, investing as an angel, serving on boards, and writing - all at the same time.

The CEO coaching practice reflects his operational philosophy: data, not inspiration. The case for coaching isn't that it feels good; it's that CEOs with coaches achieve 40% higher exit valuations and are 3.5x more likely to reach an IPO. Johnson structures his coaching in two tiers - Minor League for earlier-stage founders, Premier League for those scaling toward significant exits - with weekly one-on-ones, peer groups, and advisory board access. His pitch is essentially the same pitch he'd make for any good investment: the numbers justify it.

Then there are the books. Johnson published two Nobel laureate biographies in quick succession: Move 37: The Life of Demis Hassabis, tracing the DeepMind co-founder who won the Nobel Prize in Chemistry, and Not Insects: The Life of Geoffrey Hinton, the first definitive biography of the Godfather of AI, who spent fifty years pursuing a theory almost everyone in science thought was a dead end - and was proven spectacularly right. Both books were published in 2024-2025, timed to the public reckoning with what modern AI actually means. For a GP investing in AI companies, writing the definitive accounts of the two scientists most responsible for the technology is not a side project. It's a way of understanding exactly what you're betting on.

In February 2025, Flex Capital announced Paul Johnson as its newest General Partner - joining Tod Sacerdoti (BrightRoll, Pipedream) and Auren Hoffman (LiveRamp, SafeGraph). The fund's thesis: founders backing founders. All three GPs have built and exited significant companies; none of them arrived at venture without first navigating the founder's chair themselves.

Flex Capital's portfolio now spans 200+ companies across AI, fintech, developer tools, and enterprise software. Among them: Perplexity, Chime, Vercel, Replit, Rippling, Supabase, Superhuman, Gusto, Retool, Carta, Tailscale, AngelList, and Mercury. Thirteen unicorns, three IPOs, nine acquisitions. Johnson's investment sweet spot is $300K at seed and pre-seed, with a particular focus on AI founders - the area where his biographical research and his investment thesis have converged into something unusual: an investor who has spent the past year living inside the minds of the scientists who built the technology he's betting on.

He grew up partly in the Netherlands - his family relocated there when he was eight, and he attended the British School until he was sixteen before returning to the English countryside. He learned to play competitive tennis. He taught himself to code. He founded something in a garage. He moved to San Francisco in his twenties with a healthcare startup and a British accent. None of this is the typical VC biography - and that difference, compounded over decades, is exactly what makes his perspective worth something.